REDWOOD
CITY, Calif., Oct. 10,
2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a
global medical device company delivering comprehensive,
life-changing solutions for the treatment of chronic pain, today
announced that it will release its financial results for the third
quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also
host a conference call beginning at 1:30
p.m. PST (4:30 p.m. EST) to
discuss its financial results.
The live webcast and replay of the conference call will be
available in the Investor Relations section of the company's
website at Events & Presentations. The webcast can be accessed
10 minutes prior to the conference call start time.
For those parties that do not have internet access, the
conference call can be accessed by calling one of the below
telephone numbers and providing conference ID 5980028:
|
U.S. domestic
participant dial-in number (toll-free):
|
1-(888)
596-4144
|
|
|
|
International
participant dial-in number:
|
1-(646)
968-2525
|
About Nevro
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on delivering comprehensive, life-changing solutions that continue
to set the standard for enduring patient outcomes in chronic pain
treatment. The company started with a simple mission to help more
patients suffering from debilitating pain and developed its
proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic
innovation that has impacted the lives of more than 115,000
patients globally. Nevro's comprehensive HFX™ spinal cord
stimulation (SCS) platform includes the Senza® SCS
system and support services for the treatment of chronic pain of
the trunk and limb and painful diabetic neuropathy.
Nevro recently added a minimally invasive treatment option for
patients suffering from chronic sacroiliac joint ("SI joint") pain
and now provides the most comprehensive portfolio of products in
the SI joint fusion space, designed to meet the preferences of
physicians and varying patient needs in order to improve outcomes
and quality of life for patients.
Senza®, Senza II®, Senza Omnia™, and HFX iQ are the
only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.
Nevro's unique support services provide every patient with an HFX
Coach™ throughout their pain relief journey and every physician
with Nevrocloud™ insights for enhanced patient and practice
management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz
Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm,
HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo,
HFX COACH, the HFX Coach logo, Nevrocloud, RELIEF MULTIPLIED,
HFX AdaptivAI, the X logo, NEVRO, and the NEVRO logo are trademarks
or registered trademarks of Nevro Corp. Patents covering Senza HFX
iQ and other Nevro products are listed at Nevro.com/patents.
Bluetooth® and the Bluetooth symbol are registered
trademarks of their respective owners.
To learn more about Nevro, connect with us on LinkedIn, X,
Facebook, and Instagram.
Investors and Media:
Angie McCabe
Vice President, Investor Relations & Corporate
Communications
angeline.mccabe@nevro.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nevro-to-report-third-quarter-2024-financial-results-and-host-earnings-conference-call-on-november-11-2024-302273410.html
SOURCE Nevro Corp.
